KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2025)

Recursion Pharmaceuticals' Cash from Operations history spans 6 years, with the latest figure at 46073000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 60.09% year-over-year to 46073000.0; the TTM value through Dec 2025 reached 371808000.0, down 3.52%, while the annual FY2025 figure was 371808000.0, 3.52% down from the prior year.
  • Cash from Operations reached 46073000.0 in Q4 2025 per RXRX's latest filing, up from 117360000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 77388000.0 in Q1 2022 to a low of 131957000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 63045000.0, with a median of 64545000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: tumbled 813.38% in 2021, then surged 351.63% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 61158000.0 in 2021, then increased by 26.83% to 44748000.0 in 2022, then tumbled by 65.54% to 74077000.0 in 2023, then plummeted by 55.82% to 115430000.0 in 2024, then skyrocketed by 60.09% to 46073000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Cash from Operations are 46073000.0 (Q4 2025), 117360000.0 (Q3 2025), and 76418000.0 (Q2 2025).